AAPL298.01+2.06 (+0.70%) ▲|ABBV216.49-4.74 (-2.14%) ▼|ABT88.41-0.09 (-0.10%) ▼|ACN127.98-28.03 (-17.97%) ▼|ADBE195.16-1.12 (-0.57%) ▼|AMAT617.11+24.19 (+4.08%) ▲|AMD537.37+24.89 (+4.86%) ▲|AMGN337.60-4.06 (-1.19%) ▼|AMT176.05-5.04 (-2.78%) ▼|AMZN244.39+6.89 (+2.90%) ▲|AVGO411.35+18.45 (+4.70%) ▲|AXP338.00-2.54 (-0.75%) ▼|BA222.72-2.91 (-1.29%) ▼|BAC56.20-0.33 (-0.58%) ▼|BKNG171.78+0.15 (+0.09%) ▲|BLK1,050.09-7.29 (-0.69%) ▼|BMY54.00-1.28 (-2.32%) ▼|BNY143.63-2.44 (-1.67%) ▼|BRK-B489.46-1.82 (-0.37%) ▼|C143.06-0.72 (-0.50%) ▼|CAT985.82+29.90 (+3.13%) ▲|CL89.48-1.10 (-1.21%) ▼|CMCSA22.43-0.26 (-1.15%) ▼|COF201.53+0.66 (+0.33%) ▲|COP107.74-3.47 (-3.12%) ▼|COST951.45-14.14 (-1.46%) ▼|CRM151.78-3.24 (-2.09%) ▼|CSCO119.54+2.21 (+1.88%) ▲|CVS98.32-0.84 (-0.85%) ▼|CVX173.63-3.95 (-2.22%) ▼|DE589.24+0.77 (+0.13%) ▲|DHR177.17-0.59 (-0.33%) ▼|DIS103.89+3.03 (+3.00%) ▲|DUK123.86+0.13 (+0.11%) ▲|EMR150.66+1.66 (+1.11%) ▲|FDX326.20+0.27 (+0.08%) ▲|GD350.01-12.82 (-3.53%) ▼|GE357.64+0.61 (+0.17%) ▲|GEV1,109.73+60.87 (+5.80%) ▲|GILD123.76-1.69 (-1.35%) ▼|GM79.29-0.29 (-0.36%) ▼|GOOG367.46+5.36 (+1.48%) ▲|GOOGL368.03+4.24 (+1.17%) ▲|GS1,096.56-2.58 (-0.23%) ▼|HD334.28+6.80 (+2.08%) ▲|HON229.01+0.40 (+0.18%) ▲|IBM249.10-13.25 (-5.05%) ▼|INTC133.99+12.89 (+10.64%) ▲|INTU267.00-2.08 (-0.77%) ▼|ISRG406.78+4.60 (+1.14%) ▲|JNJ228.39-5.81 (-2.48%) ▼|JPM325.22-8.24 (-2.47%) ▼|KO79.39-0.54 (-0.68%) ▼|LIN512.15-3.70 (-0.72%) ▼|LLY1,098.57-13.43 (-1.21%) ▼|LMT510.95-21.37 (-4.01%) ▼|LOW222.20+4.93 (+2.27%) ▲|LRCX389.04+14.86 (+3.97%) ▲|MA489.79-3.20 (-0.65%) ▼|MCD278.61-5.21 (-1.84%) ▼|MDLZ60.12-0.74 (-1.22%) ▼|MDT79.34+1.20 (+1.54%) ▲|META577.22+9.64 (+1.70%) ▲|MMM160.60+1.37 (+0.86%) ▲|MO69.12+0.17 (+0.25%) ▲|MRK113.87-1.57 (-1.36%) ▼|MS223.17-1.79 (-0.80%) ▼|MSFT379.40+0.49 (+0.13%) ▲|MU1,133.99+90.80 (+8.70%) ▲|NEE86.75+1.02 (+1.19%) ▲|NFLX77.38+0.42 (+0.55%) ▲|NKE45.20+1.01 (+2.29%) ▲|NOW95.04-0.44 (-0.46%) ▼|NVDA210.69+6.04 (+2.95%) ▲|ORCL184.29+0.76 (+0.41%) ▲|PEP142.02+0.43 (+0.30%) ▲|PFE25.21-0.71 (-2.74%) ▼|PG150.38-0.18 (-0.12%) ▼|PLTR128.47-2.16 (-1.65%) ▼|PM178.40-1.04 (-0.58%) ▼|QCOM226.11+13.14 (+6.17%) ▲|RTX185.60-6.98 (-3.62%) ▼|SBUX100.65+0.83 (+0.83%) ▲|SCHW91.70-2.81 (-2.97%) ▼|SO93.09+0.56 (+0.61%) ▲|SPG211.33+1.47 (+0.70%) ▲|T22.01-0.43 (-1.92%) ▼|TMO464.61+2.92 (+0.63%) ▲|TMUS181.67+0.36 (+0.20%) ▲|TSLA400.49+4.11 (+1.04%) ▲|TXN322.86+20.98 (+6.95%) ▲|UBER71.64+0.73 (+1.03%) ▲|UNH400.96+1.43 (+0.36%) ▲|UNP256.88-1.17 (-0.45%) ▼|UPS104.86-0.27 (-0.26%) ▼|USB58.14+0.23 (+0.40%) ▲|V327.24-3.14 (-0.95%) ▼|VZ45.37-0.47 (-1.03%) ▼|WFC82.20-1.61 (-1.92%) ▼|WMT117.18-0.95 (-0.80%) ▼|XOM137.81-2.93 (-2.08%) ▼|AAPL298.01+2.06 (+0.70%) ▲|ABBV216.49-4.74 (-2.14%) ▼|ABT88.41-0.09 (-0.10%) ▼|ACN127.98-28.03 (-17.97%) ▼|ADBE195.16-1.12 (-0.57%) ▼|AMAT617.11+24.19 (+4.08%) ▲|AMD537.37+24.89 (+4.86%) ▲|AMGN337.60-4.06 (-1.19%) ▼|AMT176.05-5.04 (-2.78%) ▼|AMZN244.39+6.89 (+2.90%) ▲|AVGO411.35+18.45 (+4.70%) ▲|AXP338.00-2.54 (-0.75%) ▼|BA222.72-2.91 (-1.29%) ▼|BAC56.20-0.33 (-0.58%) ▼|BKNG171.78+0.15 (+0.09%) ▲|BLK1,050.09-7.29 (-0.69%) ▼|BMY54.00-1.28 (-2.32%) ▼|BNY143.63-2.44 (-1.67%) ▼|BRK-B489.46-1.82 (-0.37%) ▼|C143.06-0.72 (-0.50%) ▼|CAT985.82+29.90 (+3.13%) ▲|CL89.48-1.10 (-1.21%) ▼|CMCSA22.43-0.26 (-1.15%) ▼|COF201.53+0.66 (+0.33%) ▲|COP107.74-3.47 (-3.12%) ▼|COST951.45-14.14 (-1.46%) ▼|CRM151.78-3.24 (-2.09%) ▼|CSCO119.54+2.21 (+1.88%) ▲|CVS98.32-0.84 (-0.85%) ▼|CVX173.63-3.95 (-2.22%) ▼|DE589.24+0.77 (+0.13%) ▲|DHR177.17-0.59 (-0.33%) ▼|DIS103.89+3.03 (+3.00%) ▲|DUK123.86+0.13 (+0.11%) ▲|EMR150.66+1.66 (+1.11%) ▲|FDX326.20+0.27 (+0.08%) ▲|GD350.01-12.82 (-3.53%) ▼|GE357.64+0.61 (+0.17%) ▲|GEV1,109.73+60.87 (+5.80%) ▲|GILD123.76-1.69 (-1.35%) ▼|GM79.29-0.29 (-0.36%) ▼|GOOG367.46+5.36 (+1.48%) ▲|GOOGL368.03+4.24 (+1.17%) ▲|GS1,096.56-2.58 (-0.23%) ▼|HD334.28+6.80 (+2.08%) ▲|HON229.01+0.40 (+0.18%) ▲|IBM249.10-13.25 (-5.05%) ▼|INTC133.99+12.89 (+10.64%) ▲|INTU267.00-2.08 (-0.77%) ▼|ISRG406.78+4.60 (+1.14%) ▲|JNJ228.39-5.81 (-2.48%) ▼|JPM325.22-8.24 (-2.47%) ▼|KO79.39-0.54 (-0.68%) ▼|LIN512.15-3.70 (-0.72%) ▼|LLY1,098.57-13.43 (-1.21%) ▼|LMT510.95-21.37 (-4.01%) ▼|LOW222.20+4.93 (+2.27%) ▲|LRCX389.04+14.86 (+3.97%) ▲|MA489.79-3.20 (-0.65%) ▼|MCD278.61-5.21 (-1.84%) ▼|MDLZ60.12-0.74 (-1.22%) ▼|MDT79.34+1.20 (+1.54%) ▲|META577.22+9.64 (+1.70%) ▲|MMM160.60+1.37 (+0.86%) ▲|MO69.12+0.17 (+0.25%) ▲|MRK113.87-1.57 (-1.36%) ▼|MS223.17-1.79 (-0.80%) ▼|MSFT379.40+0.49 (+0.13%) ▲|MU1,133.99+90.80 (+8.70%) ▲|NEE86.75+1.02 (+1.19%) ▲|NFLX77.38+0.42 (+0.55%) ▲|NKE45.20+1.01 (+2.29%) ▲|NOW95.04-0.44 (-0.46%) ▼|NVDA210.69+6.04 (+2.95%) ▲|ORCL184.29+0.76 (+0.41%) ▲|PEP142.02+0.43 (+0.30%) ▲|PFE25.21-0.71 (-2.74%) ▼|PG150.38-0.18 (-0.12%) ▼|PLTR128.47-2.16 (-1.65%) ▼|PM178.40-1.04 (-0.58%) ▼|QCOM226.11+13.14 (+6.17%) ▲|RTX185.60-6.98 (-3.62%) ▼|SBUX100.65+0.83 (+0.83%) ▲|SCHW91.70-2.81 (-2.97%) ▼|SO93.09+0.56 (+0.61%) ▲|SPG211.33+1.47 (+0.70%) ▲|T22.01-0.43 (-1.92%) ▼|TMO464.61+2.92 (+0.63%) ▲|TMUS181.67+0.36 (+0.20%) ▲|TSLA400.49+4.11 (+1.04%) ▲|TXN322.86+20.98 (+6.95%) ▲|UBER71.64+0.73 (+1.03%) ▲|UNH400.96+1.43 (+0.36%) ▲|UNP256.88-1.17 (-0.45%) ▼|UPS104.86-0.27 (-0.26%) ▼|USB58.14+0.23 (+0.40%) ▲|V327.24-3.14 (-0.95%) ▼|VZ45.37-0.47 (-1.03%) ▼|WFC82.20-1.61 (-1.92%) ▼|WMT117.18-0.95 (-0.80%) ▼|XOM137.81-2.93 (-2.08%) ▼|
22.9 C
New York
Monday, June 22, 2026

Tag: therapies

newssourceFORcompanyinformationcontent1marketreleases

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

2H 2025 is shaping up to be a defining year for LIXTE (Nasdaq: LIXT) and its lead compound LB-100

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH 
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in...

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3...

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts...

Breakthrough T1D-Authored Paper Paves the Way for Beta Cell Replacement Therapies on the Path to Cures for Type 1 Diabetes

Changes recommended in clinical trial design to include the voice of more people living with type 1 diabetes in evaluating therapy benefits NEW YORK, Aug....

Made Scientific and New Jersey Delegates Celebrate Grand Opening of Flagship Cell Therapy Manufacturing Facility

New Jersey Department of Labor Commissioner Robert Asaro-Angelo, Assemblywoman Tennille McCoy, Plainsboro Township Mayor Edmund Yates, Middlesex County Board of Commissioners Director Ronald Rios,...

Zifo Launches AI Antibody Engineering App on Snowflake Marketplace to Accelerate Biologics and Drug Discovery

Zifo accelerates antibody engineering and therapeutics development with launch of AI-Powered Protein Models on Snowflake CAMBRIDGE, Mass., CAMBRIDGE, England and CHENNAI, India, Aug. 14,...

Norgine completes acquisition of Theravia

PARIS, Aug. 14, 2025 /PRNewswire/ -- Norgine today announced the successful completion of the acquisition of Theravia, an international pharmaceutical company specialising in therapies for...

Whole Genome Sequencing Market to Reach New Heights by 2030

"With cutting-edge advances in next-generation sequencing and growing interest in personalized medicine, whole genome sequencing is set to transform disease diagnosis and treatment, driving...

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT – Advancing Breakthrough Therapy for Chronic Lower Back Pain

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease (DDD), a major cause of chronic lower back pain and disability.

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers